Unpacking Averages: Exploring Data on FDA’s Breakthrough Device Program Obtained Through FOIA
The article reveals significant transparency gaps in how the FDA manages its Breakthrough Device Program, as many designated devices remain unapproved for years. By obtaining internal data via a Freedom of Information Act request, the author highlights that while the program aims to accelerate access to innovative technologies, the actual outcomes suggest a high attrition rate and potential inefficiencies in resource allocation. This discrepancy between designation and final approval raises questions about whether the current framework effectively serves public health needs or merely adds administrative burdens for sponsors. Analysis of the internal data uncovers a bimodal distribution in review times, with decisions clustering around thirty or sixty days, though the reasons for this pattern remain unclear. Furthermore, the detailed breakdown by specific FDA review teams shows that innovation is heavily concentrated in orthopedic and cardiovascular subfields. This granularity, previously unavailable in public reports, illustrates where industry investment and regulatory attention are currently focused, allowing stakeholders to assess if these priorities align with the most critical unmet clinical needs. This information is vital for the open data community because it demonstrates the value of leveraging public records laws to access non-public government data. It underscores how transparency initiatives can expose operational nuances that are not visible through standard public reporting. For those interested in open data, this case serves as a practical example of how FOIA requests can complement public datasets, enabling more comprehensive analysis of regulatory processes and fostering informed policy discussions regarding government efficiency and accountability.
Source: natlawreview.comPublished on 2024-12-18